Filing Details
- Accession Number:
- 0000875320-23-000060
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-15 16:33:17
- Reporting Period:
- 2023-12-13
- Accepted Time:
- 2023-12-15 16:33:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-12-13 | 13,254 | $399.41 | 9,171 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-12-13 | 100 | $400.19 | 9,071 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $399.41 (range $399.00 to $399.97).
Billionaire Hedge Funds
